• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mainz Biomed N.V. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    6/26/26 5:00:15 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QUCY alert in real time by email
    false 0001874252 00-0000000 0001874252 2026-06-22 2026-06-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 22, 2026

     

    Quantum Cyber N.V.

    (Exact Name of Registrant as Specified in its Charter)

     

    The Netherlands   001-41010   N/A

    (State or Other Jurisdiction

    of Incorporation)

      (Commission File Number)  

    (I.R.S. Employer

    Identification No.)

     

    1501 Belvedere Road Suite 500, West Palm Beach, FL 33406

    (Address of Principal Executive Offices) (Zip Code)

     

    +1 (561) 562-4111

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange On Which Registered
    Ordinary Shares, nominal value €0.01 per share   QUCY   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

      

     

     

      

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    (a) Dismissal of Independent Registered Public Accounting Firm

     

    On June 22, 2026, the Audit Committee of the Board of Directors (the “Committee”) of Quantum Cyber N.V. (the “Company”) approved the dismissal of Reliant CPA PC (“Reliant”) as the Company’s independent registered public accounting firm, effective as of the same date.

      

    The reports of Reliant on the Company’s consolidated financial statements for the fiscal years ended December 31, 2025 and December 31, 2024, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except as follows: Reliant’s report on the consolidated financial statements of the Company as of December 31, 2025 and 2024 and for each of the years then ended, contained a separate paragraph stating, “The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.”

     

    From January 17, 2023, the date of Reliant’s appointment, through June 22, 2026, the date of Reliant’s dismissal, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Reliant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Reliant, would have caused Reliant to make reference to such disagreement in its reports, if such reports had been issued, and (b) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions).

     

    The Company provided Reliant with a copy of this Current Report on Form 8-K prior to its filing with the U.S. Securities and Exchange Commission (the “SEC”) and requested that Reliant furnish the Company with a letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation S-K, stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter, dated June 26, 2026, is filed as Exhibit 16.1 (which is incorporated by reference herein) to this Current Report on Form 8-K.

     

    (b) Appointment of New Independent Registered Public Accounting Firm

     

    On June 22, 2026, the Committee engaged Haskell & White LLP (“Haskell & White”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, effective immediately. During the fiscal years ended December 31, 2025, and December 31, 2024, and the subsequent interim period through June 22, 2026, neither the Company nor anyone on its behalf has consulted with Haskell & White regarding (i) the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that Haskell & White concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K, or a “reportable event,” as defined in Item 304(a)(1)(v) of Regulation S-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    16.1   Letter from Reliant CPA PC to the Securities and Exchange Commission dated June 26, 2026.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Quantum Cyber N.V.
         
      By: /s/ William Caragol
      Name: William Caragol
      Title: Chief Financial Officer
         
    Dated: June 26, 2026    

      

    2

     

    Get the next $QUCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QUCY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QUCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quantum Cyber Completes Acquisition of U.S.-Based Manufacturing Facility in Bridgeport, Connecticut

    WEST PALM BEACH, Florida, July 16, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that its wholly owned subsidiary, Quantum Drones Corporation, has completed the acquisition of certain parcels of real property located at 38 Union Avenue, Bridgeport, Connecticut, for a purchase price of $2,300,000. The transaction closed on July 15, 2026. The closing completes the real-property component of the Bridgeport acquisition that the Company first announced through a

    7/16/26 4:05:00 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation

    WEST PALM BEACH, Florida, July 16, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today reported purchase orders of approximately $2.09 million at the Company’s wholly- owned subsidiary, Quantum Drones Corporation who assumed these open purchase orders. These orders were received as part of the Company’s acquisition of a 50,000 square foot manufacturing facility. This acquisition is intended to anchor the Company’s transition and future growth toward direct, U.S.-based manu

    7/16/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Completes Confidential Submission to U.S. Army Program

    WEST PALM BEACH, Florida, July 08, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that it has completed and submitted a confidential concept white paper and accompanying technical demonstration video to a technology program sponsored by a branch of the United States Army. The program is structured as a multi-phase, competitive down-select process open to select small and large businesses developing dual-use, autonomous capability for contested, distributed m

    7/8/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    SEC Filings

    View All

    Mainz Biomed N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Quantum Cyber N.V. (0001874252) (Filer)

    7/16/26 4:05:26 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Quantum Cyber N.V. (0001874252) (Filer)

    7/1/26 4:05:20 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed N.V. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Quantum Cyber N.V. (0001874252) (Filer)

    6/26/26 5:00:15 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    Leadership Updates

    Live Leadership Updates

    View All

    Former Trump Administration VA Secretary Peter O'Rourke Sr. Joins Quantum Cyber's Board of Directors

    WEST PALM BEACH, Fla, May 14, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a company assembling an AI-powered System-of-Systems autonomous defense platform spanning drone warfare, counter-UAS, demining, and command-and-control applications, today announced the appointment of Peter M. O'Rourke Sr. as an independent member of its Board of Directors, effective immediately. Mr. O'Rourke served as Acting Secretary of the U.S. Department of Veterans Affairs (VA) under the Trump administration in 2018, where he led over 380,000 employees and helped oversee one of the largest federal healthcare and benefits systems in the country, with an annual bu

    5/14/26 8:01:00 AM ET
    $NVAC
    $PFSA
    $QUCY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $QUCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Buffalino Louis R. claimed no ownership of stock in the company (SEC Form 3)

    3 - Quantum Cyber N.V. (0001874252) (Issuer)

    7/9/26 5:00:21 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director O'Rourke Peter

    4 - Quantum Cyber N.V. (0001874252) (Issuer)

    7/7/26 6:02:30 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ben-Tzvi Avraham was granted 137,141 units of Ordinary Shares, increasing direct ownership by 6,857% to 139,141 units (SEC Form 4)

    4 - Quantum Cyber N.V. (0001874252) (Issuer)

    5/26/26 6:12:13 PM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QUCY
    Financials

    Live finance-specific insights

    View All

    Quantum Cyber Reports Approximately $2 Million of Purchase Orders for Quantum Drone Corporation

    WEST PALM BEACH, Florida, July 16, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today reported purchase orders of approximately $2.09 million at the Company’s wholly- owned subsidiary, Quantum Drones Corporation who assumed these open purchase orders. These orders were received as part of the Company’s acquisition of a 50,000 square foot manufacturing facility. This acquisition is intended to anchor the Company’s transition and future growth toward direct, U.S.-based manu

    7/16/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Completes Confidential Submission to U.S. Army Program

    WEST PALM BEACH, Florida, July 08, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that it has completed and submitted a confidential concept white paper and accompanying technical demonstration video to a technology program sponsored by a branch of the United States Army. The program is structured as a multi-phase, competitive down-select process open to select small and large businesses developing dual-use, autonomous capability for contested, distributed m

    7/8/26 7:30:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Cyber Targets Annual Production Capacity of 100,000 Drones combining Kamikaze, Interceptor, Surveillance, VTOL and long-range Phantom 950 at Planned Bridgeport, Connecticut Manufacturing Facility

    WEST PALM BEACH, Florida, July 06, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced projected production capacity targets for its proposed Bridgeport, Connecticut manufacturing facility, including an estimated annual output of approximately 100,000 drones upon completion of the facility and full operational modification and buildout. The production capacity targets are based on the Company’s current assessment of the facility’s manufacturing footprint and the

    7/6/26 8:00:00 AM ET
    $QUCY
    Biotechnology: Pharmaceutical Preparations
    Health Care